Aldosterone and PAI-1: Implications for renal injury

Journal of Nephrology

Volumn 15, Issue 3, 2002, Pages 230-235

  Brown, Nancy J ^a   Vaughan, Douglas E ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Aldosterone; Angiotensin converting enzyme inhibitor; Fibrosis; Plasminogen activator inhibitor 1

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE;

BIOACCUMULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE MODEL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSIS; HEART MUSCLE FIBROSIS; HORMONE PROTEIN COMPLEX; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; INJURY; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALDOSTERONE; FIBROSIS; HUMAN; KIDNEY; KIDNEY DISEASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0035985329     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Mechanisms of action of mineralocorticoid hormones
2. On the biochemical mechanism of action of aldosterone
3. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor
4. Aldosterone biosynthesis and action in vascular cells
5. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin
6. Production of aldosterone in isolated rat blood vessels
7. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation
8. Aldosterone-specific membrane receptors and related rapid, non-genomic effects
9. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension
10. Biological determinants of aldosterone-induced cardiac fibrosis in rats
11. Mineralocorticoids, hypertension, and cardiac fibrosis
12. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
13. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
14. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone
15. Role of aldosterone in the remnant kidney model in the rat
16. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
17. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone
18. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
19. Cell-associated plasminogen activation: Regulation and physiologic functions
20. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
21. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls
22. Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1
23. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis
24. PAI-1, obesity, insulin resistance and risk of cardiovascular events
25. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin
26. TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes
27. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
28. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
29. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain
30. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells
31. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
32. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells
33. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
34. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo
35. Angiotensin II and angiotensin IV induce PAI-1 expression through a shared promoter element
36. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression
37. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
38. Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase
39. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans
40. Spironolactone abolishes the relationship between aldosterone and PAI-1 in humans
41. Activation of the renin-angiotensin system through dietary sodium restriction increases plasminogen activator inhibitor type 1 levels in essential hypertension
42. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
43. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
44. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter
45. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses
46. Potentiation of angiotensin II action by corticosteroids in vascular tissue
47. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: Role in aldosterone-salt-induced fibrosis
48. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis
49. PAI-1, fibrosis, and the elusive provisional fibrin matrix
50. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
51. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype
52. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts
53. Proteinases and extracellular matrix remodeling
54. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
55. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to chronic nitric oxide synthase inhibition
56. Treatment of radiation nephropathy with captopril
57. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
58. Transforming growth factor (TGF)-β dependent and independent pathways of induction of tubulointerstitial fibrosis in αvβ6-/- mice
59. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis
60. The relation between endothelial dysfunction of coronary artery and major adverse coronary events
61. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
62. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
63. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
64. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure
65. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
66. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator-1 activity
67. Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction
68. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
69. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women
70. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians
71. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen